GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus

Inclusion Criteria: * Males and females 18-70 years of age * Chronic HCV infection * Subjects must have liver biopsy results (≤ 2 years prior to Screening) indicating the absence of cirrhosis. * Monoinfection with HCV genotype 1 * HCV RNA \> 10\^4 IU/mL at Screening * HCV treatment naïve * Candidate for PEG/RBV therapy * Body mass index (BMI) 18-36 kg/m2, inclusive * Agree to use two forms of highly effective contraception methods for the duration of the study and for 7 months after the last dose of study medication. Females of childbearing potential must have negative pregnancy test at Screening and Baseline. Exclusion Criteria: * Pregnant female or male with pregnant female partner * Exceed defined thresholds for leukopenia, neutropenia, anemia, thrombocytopenia, thyroid stimulating hormone (TSH) * Diagnosis of autoimmune disease, decompensated liver disease, poorly controlled diabetes mellitus, significant psychiatric illness, severe chronic obstructive pulmonary disease (COPD), HIV, hepatitis B virus (HBV), hepatocellular carcinoma or other malignancy (with exception of certain resolved skin cancers), hemoglobinopathy, retinal disease, or are immunosuppressed. * Subjects with current use of amphetamines, cocaine, opiates (e.g., morphine, heroin), or ongoing alcohol abuse are excluded. Patients on stable methadone or buprenorphine maintenance treatment for at least 6 months prior to Screening may be included into the study.